[go: up one dir, main page]

CL2016000027A1 - Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. - Google Patents

Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán.

Info

Publication number
CL2016000027A1
CL2016000027A1 CL2016000027A CL2016000027A CL2016000027A1 CL 2016000027 A1 CL2016000027 A1 CL 2016000027A1 CL 2016000027 A CL2016000027 A CL 2016000027A CL 2016000027 A CL2016000027 A CL 2016000027A CL 2016000027 A1 CL2016000027 A1 CL 2016000027A1
Authority
CL
Chile
Prior art keywords
pharmaceutical dosage
atrasentán
dosage forms
stabilized pharmaceutical
atrasentan
Prior art date
Application number
CL2016000027A
Other languages
English (en)
Inventor
Ye Huang
Andrew K Koski
Katherine E Peterson
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CL2016000027A1 publication Critical patent/CL2016000027A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA FORMA DE DOSIFICACION FARMACEUTICA SOLIDA ESTABLE QUE COMPRENDE A) 0,25 A 1,25 MG DE ATRASENTAN Y B) UN ANTIOXIDANTE, EN DONDE LA RELACION MOLAR DE ANTIOXIDANTE A ATRASENTAN ES 10:1 A 1:10, Y C) UN DILUYENTE; RECIPIENTE QUE LA COMPRENDE, UTIL PARA EL TRATAMIENTO DE UNA NEFROPATIA.
CL2016000027A 2013-07-08 2016-01-07 Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. CL2016000027A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361843799P 2013-07-08 2013-07-08

Publications (1)

Publication Number Publication Date
CL2016000027A1 true CL2016000027A1 (es) 2016-07-22

Family

ID=51211921

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016000027A CL2016000027A1 (es) 2013-07-08 2016-01-07 Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán.
CL2016000788A CL2016000788A1 (es) 2013-07-08 2016-04-05 Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2016000788A CL2016000788A1 (es) 2013-07-08 2016-04-05 Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016)

Country Status (19)

Country Link
US (2) US9364458B2 (es)
EP (1) EP3019158A1 (es)
JP (1) JP2016530238A (es)
KR (1) KR20160029125A (es)
CN (1) CN105517541A (es)
AU (1) AU2014287496A1 (es)
CA (1) CA2916033C (es)
CL (2) CL2016000027A1 (es)
CR (1) CR20160037A (es)
DO (1) DOP2016000003A (es)
EC (1) ECSP16005195A (es)
HK (1) HK1223825A1 (es)
IL (1) IL243242B (es)
MX (1) MX2016000188A (es)
PE (1) PE20160221A1 (es)
PH (1) PH12016500042A1 (es)
RU (1) RU2016103764A (es)
SG (2) SG10201700596PA (es)
WO (1) WO2015006219A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201700596PA (en) * 2013-07-08 2017-02-27 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
US10929741B2 (en) 2018-06-18 2021-02-23 University Of Florida Research Foundation, Incorporated Cross-registration for unclonable chipless RFID tags
CA3161516A1 (en) 2019-12-17 2021-06-24 Philip Thomas FROHLICH Methods of treating iga nephropathy with atrasentan
WO2021207723A2 (en) * 2020-04-10 2021-10-14 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
IL299568A (en) 2020-07-10 2023-02-01 Astrazeneca Ab A combination of zibutantan and dapagliflozin for the treatment of chronic kidney disease
US12156914B2 (en) * 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
IL320469A (en) 2022-10-28 2025-06-01 Chinook Therapeutics Inc Treatment of IGA nephropathy with an endothelin receptor antagonist and an APRIL-binding antibody

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US6124341A (en) 1996-02-13 2000-09-26 Abbott Laboratories Endothelin antagonists
US5801250A (en) 1996-12-13 1998-09-01 Abbott Laboratories Process for the stereoselective production of nitro-enamine compounds
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2002524546A (ja) 1998-09-14 2002-08-06 アボット・ラボラトリーズ 立体選択性ニトロ化合物の製造方法
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030022811A1 (en) 2001-04-11 2003-01-30 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2006034094A1 (en) * 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
US20060135596A1 (en) * 2004-09-17 2006-06-22 Zhang Geoff G Amorphous form of a drug
MX2007003158A (es) * 2004-09-17 2007-05-15 Abbott Lab Forma cristalina 2 del clorhidrato de atrasentan.
US9051301B2 (en) 2004-09-17 2015-06-09 Abbvie Inc. Crystalline form of a drug
AU2007225207A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Formulations of sitaxsentan sodium
US20080132710A1 (en) * 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
US20100184026A1 (en) 2009-01-22 2010-07-22 Abbott Laboratories Companion Diagnostic Assays For Endothelin Receptor Antagonists
CN102655858B (zh) * 2009-12-22 2015-11-25 Abbvie公司 Abt-263胶囊
KR20110119108A (ko) 2010-04-26 2011-11-02 울산대학교 산학협력단 포도씨 프로안토시아니딘 추출물을 유효성분으로 함유하는 폐 섬유화증 치료 및 예방용 약학조성물
CN102114005B (zh) * 2010-12-06 2012-12-12 武汉武药科技有限公司 一种波生坦胶囊及其制备方法
SG10201700596PA (en) * 2013-07-08 2017-02-27 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
US8962675B1 (en) * 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts

Also Published As

Publication number Publication date
CR20160037A (es) 2016-04-05
JP2016530238A (ja) 2016-09-29
HK1223825A1 (zh) 2017-08-11
US9364458B2 (en) 2016-06-14
US20160250186A1 (en) 2016-09-01
KR20160029125A (ko) 2016-03-14
PH12016500042A1 (en) 2016-03-28
EP3019158A1 (en) 2016-05-18
WO2015006219A1 (en) 2015-01-15
CN105517541A (zh) 2016-04-20
IL243242B (en) 2020-11-30
CA2916033C (en) 2022-08-23
SG11201600107RA (en) 2016-02-26
US10016393B2 (en) 2018-07-10
US20150011602A1 (en) 2015-01-08
PE20160221A1 (es) 2016-05-22
CL2016000788A1 (es) 2016-11-11
MX2016000188A (es) 2016-03-09
CA2916033A1 (en) 2015-01-15
AU2014287496A1 (en) 2016-01-07
SG10201700596PA (en) 2017-02-27
RU2016103764A (ru) 2017-08-11
RU2016103764A3 (es) 2018-05-31
IL243242A0 (en) 2016-02-29
ECSP16005195A (es) 2017-02-24
DOP2016000003A (es) 2016-02-15

Similar Documents

Publication Publication Date Title
CL2016000027A1 (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán.
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
DOP2015000274A (es) Compuestos químicos
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
EA201490806A1 (ru) Комбинированный состав двух противовирусных соединений
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
AR098168A1 (es) Formulación estable de insulina glulisina
GT201500247A (es) Imidazopiridazinas sustituidas
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2015002667A1 (es) Dispensador
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
EA201890828A1 (ru) Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
MX2017006709A (es) Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
ES2732368T3 (es) Bacteriófago novedoso y composición que lo contiene